PAK6 and gastric cancer: Expectedly, overexpressing the PAK6 showed a dramatical increased ratio of EGFP positive cells and high level of EGFP (Fig. 4b), which supported the fact that PAK6 could regulate HR efficacy to affect the sensitivity to oxaliplatin in GC cells.